

May 26, 2008  
AnGes MG, Inc.

**Medical Use Patent for the Combination Use of HGF and PGIS**  
**Granted in Europe**  
**- Covering Angiogenic Therapy -**

AnGes MG Inc. announces that a patent for the medicinal use of HGF gene and prostacyclin synthase (PGIS) gene used in combination for angiogenic therapy was granted in Europe, and the Patent Gazette (EP1300158B1) was issued.

The present invention features compositions related to angiogenic therapy using prostacyclin synthase gene with its vasodilatation activity as well as platelet anti-aggregation activity in addition to HGF's angiogenic activity, and encompasses more effective therapeutic pharmaceuticals for ischemic diseases such as peripheral arterial disease (PAD) and ischemic heart disease (IHD).

AnGes MG is currently promoting the development of HGF gene therapy product, and as for PAD it has submitted an application for new drug approval of "Collatogene" as a therapeutic agent for peripheral ischemic diseases in Japan in March 2008. Additionally, AnGes MG is trying to further explore more new applicable diseases of its HGF gene therapy product, while focusing on the development of a more effective preparation for gene therapy. This patent strategy has been promoted because the combination use of HGF gene and PGIS gene possesses high possibilities to come in succession of AnGes MG's ongoing HGF gene therapy product development. In addition to Europe the present invention has already been patented in Australia and China, and also patent applications are pending in Japan, USA and Canada.

This patent will support the future advancement of HGF gene therapy product, and will contribute to further establish the strong patent network of AnGes MG's HGF gene therapy product.